symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GRI,1.28,0,114504,3784128,0.489,1.092-36.9,-0.21,"GRI Bio, Inc.",USD,,,,New York Stock Exchange Arca,AMEX,Biotechnology,https://www.gribio.com,"GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.",Dr. W. Marc Hertz Ph.D.,Healthcare,US,1,619 400 1171,2223 Avenida DE LA Playa,La Jolla,CA,92037,,0,https://financialmodelingprep.com/image-stock/GRI.png,2021-02-10,False,False,True,False,False
